title: Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication.
abstract: BACKGROUND
  Increasingly and justifiably, clinical studies are now being expected to investigate the influence of therapeutic measures also on the quality of life of the patient.
  
  
  METHODS
  Since no data on the variability of changes in the quality of life of the patient following PGE1 treatment are so far available, the initial investigation was designed as an uncontrolled pilot study. 104 patients (median age 64.5 years) with a maximum of walking distance on the treadmill (3 km/12%) of 50-250 m were included and given a daily intravenous infusion of 60 micrograms PGE1 (Prostavasin) over a period of 4 weeks excluding weekends. This was followed by a treatment-free follow-up period of 3 months. Changes in the quality of life were recorded with both the newly developed disease-specific questionnaire PAVK-86, and the generic questionnaire SF 36; in addition, the pain-free and maximum walking distances on the treadmill were also established prior to and immediately following treatment, as also at the end of the follow-up period.
  
  
  RESULTS
  The quality of life was significantly improved in all dimensions (functional status, complaints, pain, mood, anxiety, social life, treatment expectations) in addition to a marked increase in the median pain-free walking distance from 77 to 108 m (p < 0.001) and the maximum walking distance from 118 to 171 m (p < 0.001). At the end of the 3-month observation period, the improvement was essentially still demonstrable.
  
  
  CONCLUSIONS
  The study has shown for the first time that treatment with intravenous PGE1 brings about not only the already known increase in the walking distance, but also a clinically relevant and significant improvement in the patient's quality of life.
authors.affiliation: Department of Angiology, Medizinische Hochschule Hannover.
authors.forename: A
authors.initials: A
authors.lastname: Creutzig
authors.forename: M
authors.initials: M
authors.lastname: Bullinger
authors.forename: M
authors.initials: M
authors.lastname: Cachovan
authors.forename: C
authors.initials: C
authors.lastname: Diehm
authors.forename: H T
authors.initials: HT
authors.lastname: Forst
authors.forename: J D
authors.initials: JD
authors.lastname: Gruss
authors.forename: S
authors.initials: S
authors.lastname: Horsch
authors.forename: W
authors.initials: W
authors.lastname: Rogatti
authors.forename: P
authors.initials: P
authors.lastname: Scheffler
authors.forename: F
authors.initials: F
authors.lastname: Spengel
authors.forename: H
authors.initials: H
authors.lastname: Stiegler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000008:administration & dosage*; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011788:Quality of Life
chemical_list: D000527:Alprostadil